Cardiothoracic & vascular anesthesia
Comparison of Sugammadex Versus Neostigmine for Postoperative Outcomes in Coronavirus Disease 2019 Patients Undergoing Thoracic Surgery: A Cohort Study
Main finding · CPCsResult — go to the resultOdds ratio 0.56Authors' conclusion
In patients with COVID-19 undergoing thoracic surgery, sugammadex was associated with a reduction in 30-day postoperative pulmonary complications compared with neostigmine.
Study context
- Population
- Adults with COVID-19 within 6 weeks before thoracic surgery985 per group after matching
- Participants
- 985 vs 985
- Exposure
- Sugammadex vs neostigmine for NMB reversal
- Sugammadexn = 985
- Neostigminen = 985reference
- Outcome
- Composite pulmonary complications (CPCs)
- Follow-up
- 30 days
Methodological detailsmatched cohort, TriNetX database
- Matched cohort
- TriNetX database
Main finding
CPCs
Odds ratio
0.56
P = 0.0009
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Pneumonia · 30 days
OR 0.41 · P = 0.0016
Respiratory failure · 30 days
OR 0.43 · P = 0.0087
Other 30-day outcomes (need for intensive care, mortality, sepsis, AKI)
- No differences found
Outcomes at 90 days
- No significant differences; mortality tended to be lower with sugammadex
Risk factors for pneumonia and respiratory failure (sugammadex recipients)
- DM and COPD identified as risk factors
Original publication
Comparison of Sugammadex Versus Neostigmine for Postoperative Outcomes in Coronavirus Disease 2019 Patients Undergoing Thoracic Surgery: A Cohort Study. J Cardiothorac Vasc Anesth. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →